Compare Gitlab Inc (GTLB) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Gitlab Inc trades at $52.47 (market cap $8.86B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Gitlab Inc is far larger — about 9.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Gitlab Inc is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GTLB | MRVI | |
|---|---|---|
Market Cap | $8.86B | $977.37M |
Volume | 6,160,270 | 2,742,564 |
Sector | Technology | Health |
52-Week High | $56.01 | $9.00 |
52-Week Low | $19.42 | $2.83 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $7.60B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $51.95, down 7.25% today but maintains strong technical momentum with bullish moving averages. The company shows accelerating revenue growth, reaching $759M in 2025, with consistent earnings beats in recent quarters. Despite negative net margins, gross margins remain exceptional at 85.75%. Recent Q2 2026 results exceeded expectations, driving positive analyst sentiment and institutional interest.
Outlook remains positive with AI-driven demand and raised guidance, though high valuation multiples and persistent cash flow challenges present risks. Wall Street maintains a cautious 'Hold' consensus with $49.71 target, but recent earnings momentum suggests potential upside if execution continues.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
